291 related articles for article (PubMed ID: 20191326)
21. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
Yoon DH; Choi DR; Ahn HJ; Kim S; Lee DH; Kim SW; Park BH; Yoon SO; Huh J; Lee SW; Suh C
Eur J Haematol; 2010 Aug; 85(2):149-57. PubMed ID: 20477862
[TBL] [Abstract][Full Text] [Related]
23. [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases].
Xu RH; Jiang WQ; Li YH; Lin TY; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):191-4. PubMed ID: 12812658
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
[TBL] [Abstract][Full Text] [Related]
25. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.
Avilés A; Neri N; Huerta-Guzmán J
J Surg Oncol; 2002 Jun; 80(2):111-5. PubMed ID: 12173380
[TBL] [Abstract][Full Text] [Related]
26. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
27. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
28. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
29. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
30. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
31. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
33. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
[TBL] [Abstract][Full Text] [Related]
34. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
Rueda A; Sabin P; Rifá J; Llanos M; Gómez-Codina J; Lobo F; García R; Herrero J; Provencio M; Jara C;
Hematol Oncol; 2008 Mar; 26(1):27-32. PubMed ID: 17868190
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
36. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
37. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
38. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma.
Møller MB; Pedersen NT; Christensen BE
Am J Hematol; 2003 Oct; 74(2):94-8. PubMed ID: 14508794
[TBL] [Abstract][Full Text] [Related]
39. Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Shono Y; Morioka M; Kawamura T; Masauzi N; Kakinoki Y; Kobayashi H; Kunieda Y; Kasai M; Kurosawa M; Asaka M; Imamura M
Eur J Haematol; 2006 Nov; 77(5):403-9. PubMed ID: 16930137
[TBL] [Abstract][Full Text] [Related]
40. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
